Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2
diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists …

Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-
related glycemic excursions through augmentation of insulin and inhibition of glucagon …

Aims To review the evolution and advancement of GLP‐1 receptor agonist (GLP‐1RA)
therapy, through the lens of randomised controlled trials, from differentiating characteristics …

Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as
effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as …

Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers
blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor …

Abstract Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone, secreted in
response to ingestion of nutrients, and has important effects on several of the …

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

Diabetes is a debilitating disease characterized by chronic hyperglycemia and is often
associated with obesity. With diabetes and obesity incidence on the rise, it is imperative to …

Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …

Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease that increases
significantly cardiovascular morbidity and mortality. It is associated with obesity, insulin …